Trials / Completed
CompletedNCT01571310
Effect of Breakfast or Omission of Breakfast in T2D
Effect of Breakfast Omission on Postprandial Glycemia After Lunch and Dinner in T2D
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Tel Aviv University · Academic / Other
- Sex
- Female
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The investigators will explore the effect of omission of breakfast on postprandial hyperglycemia and insulin and intact GLP-1 response after subsequent meals in type 2 diabetic patients
Detailed description
In obesity and in type 2 diabetes eating behavior especially the lack of breakfast promote weight gain, increase hunger and carbohydrate craving. The present study is designed to address whether in T2D, a change in meal timing; specifically, by adding calories, protein and carbohydrates to the breakfast vs.the omission of breakfast will influence the postprandial elevation of glucose, insulin, intact GLP-1, glucagon and free fatty acids (FFA) after subsequent meals at lunch and dinner. The investigators expect that compared to the day with breakfast condition the day when the breakfast will be omitted the postprandial glucose , free fattly acids, and glucagon response after lunch and dinner will be significative higher while insulin and intact GLP-1 response after lunch and dinner will be reduced
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Omitted Breakfast | Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00 |
| OTHER | Breakfast | In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00 (YesB): The patients in YesB will eat all three mealswill consume three meals: |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2016-04-01
- Completion
- 2016-05-01
- First posted
- 2012-04-05
- Last updated
- 2017-10-11
Locations
2 sites across 2 countries: Israel, Venezuela
Source: ClinicalTrials.gov record NCT01571310. Inclusion in this directory is not an endorsement.